Clinical Trial Update: Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update. It studied the effect of ivacaftor on Lung Clearance Index in cystic fibrosis patients with the G551D CFTR mutation; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-30